Cholestatic Liver Disease after Rituximab and Adalimumab and the Possible Role of Cross-Reacting Antibodies to Fab 2 Fragments
Open Access
- 11 November 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (11) , e78856
Abstract
Millions of patients are treated with therapeutic monoclonal antibodies (Tmabs) for miscellaneous diseases. We investigated sera from six patients who received immune globulin, from one patient with refractory anti-neutrophil-cytoplasmic antibody (ANCA)-associated granulomatosis with polyangiitis (GPA) who developed two episodes of acute cholestatic liver disease, one after treatment with rituximab and a second after adalimumab and a healthy control group. Three sera from the patient and six sera from patients who received immune globulin were analyzed for antibodies to rituximab and adalimumab by ELISA. Additionally, sera from the patients and from nine healthy blood donors were coated with the Fab fragment of an unrelated humanized monoclonal antibody, with human Fc proteins as well as a mouse IgG globulin. Viral serology for hepatitis A, B, C and autoantibodies specific for autoimmune liver disorders were negative. In all three sera from the patient antibodies to rituximab could be detected, but also antibodies to adalimumab were present even at time points when the patient had not yet received adalimumab, indicating cross reactivity between both substances. Testing against an unrelated human Fab fragment revealed positive results, indicating that the patient had antibodies against human Fab fragments in general. The Fc proteins were negative, and patients’ sera did also not react with mouse IgG globulins. Remarkably, 2 out of 5 patients which were treated with immune globulin had antibodies against human Fab fragments in general whereas in none of the samples from healthy controls antibodies to Fab fragment could be detected. This is the first study demonstrating cholestatic liver disease induced by two different Tmabs. Cross - reacting antibodies to Fab2 fragments in general are probably involved. Further studies must show if these Fab2 antibodies in general are related with drug-induced side effects and accelerated drug clearance in patients on Tmab therapy.Keywords
This publication has 24 references indexed in Scilit:
- A Case of Rituximab-Induced HepatitisCancer Biotherapy and Radiopharmaceuticals, 2010
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- Scientific and regulatory considerations on the immunogenicity of biologicsTrends in Biotechnology, 2006
- Rituximab‐induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemiaAmerican Journal of Hematology, 2005
- Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infantArchives of Disease in Childhood, 2003
- IgG Immune Complex Binding to and Activation of Liver CellsInternational Archives of Allergy and Immunology, 2000
- Anti-Fab antibodies in humans. Predominance of minor immunoglobulin G subclasses in rheumatoid arthritis.Journal of Clinical Investigation, 1985
- OBSERVATIONS ON ANTIGAMMA GLOBULIN FACTORS IN HUMAN SERA AND ANTIBODIES AGAINST AUTOLOGOUS GAMMA GLOBULINS PRODUCED IN RABBITSAnnals of the New York Academy of Sciences, 1965
- Anti‐γ‐Globulin Factors in Human Sera Revealed by Enzymatic Splitting of Anti‐Rh Antibodies*Vox Sanguinis, 1963